ARG-007 is the novel neuroprotective therapeutic to reduce brain damage after stroke, after TBI, HIE and the list is getting longer. Alzheimer's disease is listed in the AGM presentation.
Neuren unfortunately have already come up with the term aspirin for the brain. Speaking of Neuren, the development pathways could end up looking similar so for those who have missed one boat, they could catch the next as ARG progresses through clinical trials with the phase 2 in ischaemic strike scheduled to begin in Q1 2024.
ARG-007 is the novel neuroprotective therapeutic to reduce brain...
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.0¢ |
Change
0.025(4.20%) |
Mkt cap ! $76.14M | |||
| Open | High | Low | Value | Volume |
| 60.0¢ | 62.5¢ | 60.0¢ | $212.7K | 346.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6000 | 61.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.0¢ | 90609 | 2 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
61.5¢ |
Change
0.025 ( 2.50 %) |
||||
| Open | High | Low | Volume | ||
| 60.0¢ | 62.5¢ | 60.0¢ | 40045 | ||
| Last updated 14.31pm 07/05/2024 ? | |||||
| AGN (ASX) Chart |